May 30, 2018
WELLESLEY, Mass, May 30, 2018 -- Many researchers are convinced that exosomes, which can transfer cytoplasmic ingredients, have unlimited potential in diagnostics and therapeutics, especially in oncology treatments. A new BCC Research study estimates that this global market will reach $180.0 million by 2023 and examines it by key application sectors: diagnostics, therapeutics and research tools.
Scientists believe that various biomolecules in exosomes can be profiled and, consequently, may serve as useful biomarkers for different diseases. Nucleic acids such as RNA or DNA can be isolated from exosomes and further analyzed by various techniques. From an estimated $25.0 million in 2018, this market is forecast to achieve an impressive five-year compound annual growth rate (CAGR) of 48.4%, according to BCC Research’s report, Exosome Diagnostics and Therapeutics: Global Markets.
Companies are developing unique research tools for exosome detection and isolation. Diagnostics applications are predicted to reach $150.0 million at a staggering CAGR of 63.1%. An exosome’s approach represents an opportunity to expand the liquid biopsy market, a growing sector in cancer diagnostics.
“All bodily fluids contain exosomes, which can transfer cytoplasmic ingredients to other cells, either locally or at distant sites. Although many scientific questions still need to be answered, exosomes serve as a novel and unique platform in the diagnostic and therapeutic sectors,” said Marianna Tcherpakov, BCC Research analyst. “Exosome research affects many scientific and industry trends, such as stem cell research, liquid biopsy and biomarker development.”
Research Tools Segment: Small But Growing
The current market for exosome research tools and reagents can be estimated at $2.0 million, predicted to grow at a five-year CAGR of 20.1%. The tendency over the last couple of years shows that the market is expanding at a relatively slow pace. Many scientists still prefer homemade procedures for exosome isolation and detection. Nevertheless, with growing biomarker and therapeutics development, more sophisticated tools will be needed, especially for engineering of exosome particles.
Exosome Diagnostics and Therapeutics: Global Markets( BIO149B )
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email email@example.com or visit www.bccresearch.com/media to request access to our library of market research.